{"name":"Seraxis","slug":"seraxis","ticker":"","exchange":"","domain":"","description":"Seraxis is a biotechnology company focused on developing cell therapies for diabetes. The company's lead product, Allogeneic Pancreatic Endocrine Cell Clusters, was discontinued, and they are currently exploring other therapeutic approaches.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiXkFVX3lxTFBobkpYWGFkcTF3YkdDd0pIYUVnODgwd1RpN3l0Vk5sbmVNekRzMnJUVF96cmlpTzlxc0NUSEhvczNIY3NOTUZSWERsR3g5R0VrZWlkZWJtaGc1bWViZFHSAWNBVV95cUxOMHgwRjRCNGhLd3NvN1dwbTJQNGo2ejl5bmVEZEVWY05xU3RZemJYNXkydHZmSFl5VnNVZE1kRnEwbUpOTDVoOWZTMGF1b3QzN0xGZVJSQnRIY0VwZHJoYXNla1E?oc=5","date":"2025-12-28","type":"pipeline","source":"BioInformant","summary":"Top Companies Developing Cell Therapy Treatments For Diabetes in 2026 - BioInformant","headline":"Top Companies Developing Cell Therapy Treatments For Diabetes in 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxOdUlPX0NuN0E3cDBqN0xiVUQwYks0TWQwUGQxTm9tdkQ5VlNEcmVsVEFHd2ktRmE0N3RPbWdEVkV0MXlQWkgwUXJJZ2JLYnhOZTMzUmpnR3hneFBkZHF2a0psSTk4WmcwYlliczFwUkkyNGhWZGRLd3hYcFJfRDJLYkRVcEJsdVp3SXhB?oc=5","date":"2025-04-11","type":"trial","source":"Breakthrough T1D","summary":"Cell therapies in clinical trials for type 1 diabetes - Breakthrough T1D","headline":"Cell therapies in clinical trials for type 1 diabetes - Breakthrough T1D","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxQUlRvdFp2VG5KMjl2MzBqbk5hTE42amFMYzlGSG1ONkZkdm5mWkUyV19ZVUNtRmxiVmhTZDRuSzlPM3NWT1BYYU5US0tselg3UHpKNmFmU3BTZmlrWDZxY1I1cmJHZmhiQXdmNFFZalJWYS1UU3dMemxKczBwZWJWNUVlN25kdzJPeW93aA?oc=5","date":"2024-01-05","type":"pipeline","source":"cleanroomtechnology.com","summary":"Seraxis diabetes stem cell programme meets GMP audit standards - cleanroomtechnology.com","headline":"Seraxis diabetes stem cell programme meets GMP audit standards","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxOa0x0ZjNnc1JuTTR4WGZYR05RRnZkQnVzZzFsWDRFQkVyTElNZ28ycDdwZnZEOXhQdklHVy1aUWt6cFhDaXRHMmVHVk9OZHhUVFk4ZUNqMDhQLTN0SDlBcWFFWjhLUWtnZ0YxY004SzNzSklJazJRS0tSeWUzOHRjUjRFUEt0blJnMUdQUlR0RS1iUQ?oc=5","date":"2023-09-21","type":"pipeline","source":"BioPharma Dive","summary":"Cell therapy developer closes funding round to support diabetes program - BioPharma Dive","headline":"Cell therapy developer closes funding round to support diabetes program","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxPWUFaREkxNkRQVVBqVnhGVXVVSkdLQzhLNmxfdlFvWThpZTNHd093TGVkRDBMUXhteVh6ZDJHWWQ5cE9FdXI0R3pIckRtX2lJODYyM2x6RmlpN2c5YmZWck80SGxvQ05YV0pvQk5hOG1qdWxCMzROWEVlcUl5dXA4bktfWDVKcHRoNFZuM2RST3pxdlFDN2Q5NnNtYw?oc=5","date":"2022-08-30","type":"pipeline","source":"BioSpace","summary":"Seraxis Announces Appointment of Chief Medical Officer, Dr. Paul Strumph - BioSpace","headline":"Seraxis Announces Appointment of Chief Medical Officer, Dr. Paul Strumph","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}